Outcomes Mandate National Integration With Cannabis as Medicine
Schlüsselwörter
Abstrakt
Beschreibung
Medical cannabis has been legal in parts of the USA since 1996, with the stated intention of reducing pain (both acute and chronic) as well as for treatment of multiple other conditions. The original implementation of medical cannabis in the USA was implemented in California as a compassionate measure to treat the HIV/AIDS epidemic. Additional studies have shown promising outcome for patients with multiple sclerosis, seizures, cancer, and other chronic conditions. However, there have been few comprehensive studies that have actually measured whether cannabis is an effective treatment for pain reduction. There is an absence of multistate, multicenter clinical studies with cannabis as medicine, not only in the USA but globally. With the expansion of medical cannabis into more than 38 states in the US, this type of clinical study is now feasible.
This study will utilize an anonymous novel online questionnaire to determine study participants' qualifying condition(s) for medical cannabis use, cannabis ingestion method, frequency of use, prescription drug use, and demographic information. Secondary factors will include evaluation of pain control, quality of life metrics, any adverse side effects from cannabis use, as well as changes in adjunctive treatments. Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
Termine
| Zuletzt überprüft: | 06/30/2020 |
| Zuerst eingereicht: | 05/02/2019 |
| Geschätzte Einschreibung eingereicht: | 05/07/2019 |
| Zuerst veröffentlicht: | 05/08/2019 |
| Letztes eingereichtes Update: | 07/25/2020 |
| Letztes Update veröffentlicht: | 07/28/2020 |
| Tatsächliches Startdatum der Studie: | 11/30/2018 |
| Geschätztes primäres Abschlussdatum: | 12/30/2025 |
| Voraussichtliches Abschlussdatum der Studie: | 12/30/2025 |
Zustand oder Krankheit
Intervention / Behandlung
Drug: Cannabis, Medical
Phase
Armgruppen
| Arm | Intervention / Behandlung |
|---|---|
| Experimental: Cannabis users Most patients will have used cannabis before their initial physician visit, and many current patients will be returning for an in-person follow-up. Patients will be given the survey shortly after the physician encounter to assess baseline parameters with current cannabis use. Any patient who is "cannabis-naïve", defined as no use within the past year or longer, will be placed into a separate data analysis arm. The investigators will follow up with patients again at 3, 6, 9, and 12 months with the online survey. Patients returning for their annual physician encounter will continue on the 3-month survey schedule until the end of the study, or if lost to follow-up. There may be slight variations in the interval based on state law, for example in Florida the in-person follow-up with the physician is required every 210 days, and some states allow for 2 year in-person visits. Every attempt will be made to adhere to a 3-month interval survey distribution. | |
| Experimental: Cancer prevention Non-cancer patient medical cannabis users with extensive or life-long cannabis use will be compared to the general population for incidence and prevalence of development of cancer. The hypothesis is that cannabis use acts as a cancer preventive substance. | |
| Experimental: Life-Threatening Conditions Opioids are a class of drugs naturally found in the opium poppy plant. Opioids are often used as medicines because they contain chemicals that relax the body and can relieve pain. Prescription opioids are used mostly to treat moderate to severe pain. Opioids can also make people feel very relaxed and "high" - which is why they are sometimes used for non-medical reasons. This can be dangerous because opioids can be highly addictive, and overdoses and death are common.
From 1999 to 2017, more than 700,000 people have died from a drug overdose. Around 68% of the more than 70,200 drug overdose deaths in 2017 involved an opioid.
In 2017, the number of overdose deaths involving opioids was 6 times higher than in 1999.
On average, 130 Americans die every day from an opioid overdose.
This study will focus on examining outcomes of patients that have been treated with cannabis as a replacement or alternative to life-threatening opioids or other prescription drugs. |
Zulassungskriterien
| Altersberechtigt für das Studium | 7 Years Zu 7 Years |
| Studienberechtigte Geschlechter | All |
| Akzeptiert gesunde Freiwillige | Ja |
| Kriterien | Inclusion Criteria: - Clinical diagnosis of a Qualifying Condition for Medical Marijuana - Must be 18 years or older unless they have consent from their parent or legal guardian as defined under state law parameters - Must be willing to complete online surveys at baseline and the follow up points in this study Exclusion Criteria: - None |
Ergebnis
Primäre Ergebnismaße
1. Treatment of Symptoms [Five years]
2. Monitoring Adverse Events [Five years]
Sekundäre Ergebnismaße
1. Cannabis Impact on Quality of Life [Five years]
2. Cannabis Route and Dosing [Five years]
